Joseph Shaw


A senior executive with extensive experience in Life Science Industry. Specializations in both domestic and international commercialization of Life Science technologies including pharmaceuticals, immunoassays, nanotechnology, medical devices, vaccines, and genomic products.

A history of significant accomplishments in biotech development, clinical evolvement and associated regulatory issues. This experience is combined with extensive expertise in the markets and corporate development in Canada, Europe, Asia and North and South America. He has extensive skill in building talented and successful teams in start-ups and mature mid-sized organizations in need of restructuring, while formulating winning corporate strategies and tactics for Marketing, R&D, Manufacturing, Financing, Strategic Partnering and Regulatory issues.

Mr., Shaw is a frequent speaker at International forums on biotechnology development and start-up companies and has taught at various academic intuitions in Canada, Australia and the United States. Mr. Shaw had held CEO positions in both private and publicly traded companies in Italy, Canada the United States and Australia with technologies ranging from diagnostics, pharmaceuticals and vaccines. He founded International Life Science Enterprises (ILSE) to utilize his domestic US and international expertise to expanding the global outreach of Life Science companies.  He would be pleased to discuss your international strategies with you and determine if ILSE can assist you in the achievement of your goals – please give him a call.

Colin W. Dykes, PhD

Dykes image

Colin comes from a background in molecular biology and genetics. He established Glaxo’s (now GSK) UK-based human genetics and genomics programs during the mid-90’s, resulting in the identification of mutations involved in susceptibility to migraine and psoriasis, and contributing to the discovery of the presenilin-1 gene’s involvement in early-onset Alzheimer’s disease. After moving to Variagenics Inc, a Cambridge, MA-based pharmacogenomics company in 1998, as VP Research, Dr. Dykes headed programs to develop DNA markers linked to drug response, using high-throughput sequencing to identify polymorphisms in pathways involved in drug efficacy and toxicity. After Variagenics’ successful IPO in 2000, Dr. Dykes subsequently accepted a position as Chief Scientific Officer at OpGen Inc., to commercialize Optical Mapping, a novel single-molecule DNA technology, used in genome sequencing and microbial strain characterization, including epidemiological analysis of disease outbreaks such as the 2011 E. coli 0157 outbreak in Germany. Most recently he served as Chief Scientific Officer of nanoMR Inc., an early-stage company developing an immunomagnetic capture system for rapid identification of bloodstream infections. The system will form the basis of a diagnostic product for the Clinical Microbiology and Food Safety markets. Dr. Dykes obtained his PhD from Cardiff University and performed post-doctoral research at Vanderbilt University School of Medicine, before joining Glaxo.

Sandra Lobo

Sandra Lobo

Biotechnology / Biochemistry / R&D / Molecular and Cell Biology / DNA Cloning / Startups /Vaccines / Investor & Scientific Relations / Funding & Grant Writing / Product Development & Launch

A skilled scientist with extensive experience in the development, commercialization and launch of new drugs, vaccines and medical device technologies.  Ms. Lobo’s research has provided strategic direction for companies in bio-engineering, gene-cloning, human and animal vaccines, and pharmaceuticals.  She is equally adept in the purification / characterization of proteins and enzymes, bioassay and enzyme assay development, and analytical instrumentation.

Ms. Lobo has a Ph.D. in Biomedicinal Chemistry from the School of Pharmacy – University of Maryland, an MS in Pharmacy with a major in Pharmacognosy from Prin. K.M. Kundnani College of Pharmacy – University of Bombay, and a BS in Pharmacy, Pharmaceutical Sciences from Poona College of Pharmacy – University of Poona, India.

Sandra is a sought-after speaker, having presented and authored numerous papers and reviews for key scientific / medical journals.  She is a member of the Life Science Alley of Minnesota, and is the primary inventor of U.S. patents.

Nida Shoubash

NidaShoubashMs. Shoubash has both supervisory and “hands-on” experience with entrepreneurial organizations as a founder. She recently graduated Phi Beta Kappa with a degree in Multi-cultural Human Resources. She is a native of the Middle East and is the Middle East specialist for the ILE program. Ms. Shoubash brings over a decade of entrepreneurial experience as well as firm grasp of diverse cultural knowledge to the group. Currently she is organizing ILE’s participation in Arab Health  2014 the second largest life science convention in the world, to be held in Dubai in January 2014.

Timothy Tripp

TimothyTrippTim Tripp, MS, MBA is the Director of the Biotechnology Resource Center (BRC) and the Assistant Director of the Biotechnology Institute (BTI) at the University of Minnesota. In the BRC he is responsible for providing contract biotechnology and fermentation services to industry and academia. In the BTI he is part of the top administration of a world class research institute in biotechnology. Prior to the University of Minnesota Tim was the Vice President of Corporate Development, a Scientist and Program Manager at Syntiron LLC, a vaccine research and development company located in St. Paul, MN. Here, Tim managed a 4.2 million dollar Defense Threat Reduction Agency Research Contract developing biodefense vaccines.  In addition, Tim has worked for various private and publicly traded pharmaceutical/medical device manufacturers providing product development, fermentation expertise and downstream process development for products for human use. Before this he gained experience in a gram positive pathogenesis research laboratory of where he developed expertise in animal models, molecular biology, and the use of select agents. He has co-authored 15 peer reviewed journal articles on various aspects of staphylococcus, streptococcus and enterococcus pathogenesis.

Paul Turney

Paul Turney2

Paul has more than thirty years of business development experience including the creation of Sales, Marketing and Strategic plans.  Helping technically complex businesses navigate the implementation of awareness programs is a specialty that involves a combination of marketing elements: digital (online, mobile, social), traditional sales and sales management, trade shows and conferences, strategic partnerships, and more.)  Mr. Turney has helped clients understand regulatory issues in the insurance and liability realms and has helped clients establish worldwide sales rep networks.

Motivation is key for marketing success and Mr. Turney’s experiences in the area of sales and customer service/relationship training are key ingredients to helping life science companies take firm root in the U.S.  As the need to expand sales, marketing, customer service and/or rep networks takes place within an ILE client organization, Paul can be counted on as a true business partner devoted to your success.